Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 […]
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 […]
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company […]
FORT LAUDERDALE, Fla., March 29, 2024 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (“BurgerFi”), owner of one of […]
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target […]
— Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 —— Exploring opportunities […]
ZEELAND, Mich., March 29, 2024 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected […]
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results […]
MIAMI, March 29, 2024 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose […]
Viactiv®Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately […]
INCLINE VILLAGE, Nev., March 29, 2024 (GLOBE NEWSWIRE) — Tri Pointe Homes, Inc. (NYSE: TPH) announced today that it will […]